Výsledky vyhľadávania - "Receptors, Estrogen metabolism"

A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer: Capivasertib in hormone receptor-positive advanced breast cancer

Autori: Turner, Nicholas C Oliveira, Mafalda Howell, Sacha J a ďalší

Zdroj: Future Oncol
Turner, N C, Oliveira, M, Howell, S J, Dalenc, F, Cortés, J, Gomez, H L, Hu, X, Jhaveri, K, Krivorotko, P, Loibl, S, Murillo, S M, Park, Y H, Sohn, J-H, Toi, M, Tokunaga, E, Yousef, S, Zhukova, L, Bruin, E D, Grinsted, L, Schiavon, G, Foxley, A & Rugo, H S 2024, 'A plain language summary of the CAPItello-291 study : Capivasertib in hormone receptor-positive advanced breast cancer', Future oncology (London, England), vol. 20, no. 37, pp. 2901-2913. https://doi.org/10.1080/14796694.2024.2390791

Predmety: Fulvestrant/administration & dosage, Receptors, Progesterone/metabolism, Receptor, ErbB-2, Clinical Studies as Topic, Receptor, ErbB-2/metabolism, Pyrimidines/therapeutic use, Breast Neoplasms, Middle Aged, Pyrimidines, Treatment Outcome, Breast Neoplasms/drug therapy, Receptors, Estrogen, Receptors, Plain Language Summary of Publication, Antineoplastic Combined Chemotherapy Protocols, Humans, ErbB-2/metabolism, Progesterone/metabolism, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Estrogen/metabolism, Receptors, Estrogen/metabolism, Receptors, Progesterone, Fulvestrant, Receptor

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39283299

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial: patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

Autori: Oliveira, Mafalda Rugo, Hope S Howell, Sacha J a ďalší

Zdroj: CAPItello-291 Study Group, Oliveira, M, Rugo, H S, Howell, S J, Dalenc, F, Cortes, J, Gomez, H L, Hu, X, Toi, M, Jhaveri, K, Krivorotko, P, Loibl, S, Morales Murillo, S, Okera, M, Nowecki, Z, Park, Y H, Sohn, J H, Tokunaga, E, Yousef, S, Zhukova, L, Fulford, M, Andrews, H, Wadsworth, I, D'Cruz, C & Turner, N C 2024, 'Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291) : patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial', The Lancet. Oncology, vol. 25, no. 9, pp. 1231-1244. https://doi.org/10.1016/S1470-2045(24)00373-5

Predmety: Adult, Pyrrolidines, Receptors, Progesterone/metabolism, Receptor, ErbB-2, Receptor, ErbB-2/metabolism, Breast Neoplasms, Breast Neoplasms/drug therapy, Double-Blind Method, Receptors, Antineoplastic Combined Chemotherapy Protocols, Humans, Pyrroles, Patient Reported Outcome Measures, Pyrimidines/administration & dosage, Fulvestrant/therapeutic use, Fulvestrant, Aged, Middle Aged, Pyrrolidines/administration & dosage, Progression-Free Survival, Pyrimidines, Receptors, Estrogen, Quality of Life, ErbB-2/metabolism, Progesterone/metabolism, Female, Estrogen/metabolism, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Receptors, Estrogen/metabolism, Receptors, Progesterone, Receptor

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39214106
https://research.manchester.ac.uk/en/publications/a50132f2-a6b1-4556-8637-e8f10ea2799f
https://doi.org/10.1016/S1470-2045(24)00373-5
http://www.scopus.com/inward/record.url?scp=85202486021&partnerID=8YFLogxK
https://research.manchester.ac.uk/en/publications/a50132f2-a6b1-4556-8637-e8f10ea2799f
https://doi.org/10.1016/S1470-2045(24)00373-5

An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study)

Autori: Trozzi, Rita Tuyaerts, Sandra Annibali, Daniela a ďalší

Prispievatelia: Trozzi, Rita Tuyaerts, Sandra Annibali, Daniela a ďalší

Zdroj: International journal of gynecological cancer
International Journal Of Gynecological Cancer

Predmety: Ovarian Neoplasms, Adult, Fulvestrant/administration & dosage, Antineoplastic Agents, Hormonal/therapeutic use, Sex Cord-Gonadal Stromal Tumors/drug therapy, Antineoplastic Agents, Hormonal, Genital Neoplasms, Female, Genital Neoplasms, Female/drug therapy, Ovarian Neoplasms/drug therapy, Middle Aged, 3. Good health, 03 medical and health sciences, Neoplasm Recurrence, Local/drug therapy, 0302 clinical medicine, Receptors, Estrogen, Sex Cord-Gonadal Stromal Tumors, Humans, Female, Human medicine, Prospective Studies, Receptors, Estrogen/metabolism, Neoplasm Recurrence, Local, Fulvestrant, Aged

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/40228941
https://pubmed.ncbi.nlm.nih.gov/38724237
https://hdl.handle.net/10067/2060640151162165141
https://biblio.vub.ac.be/vubir/an-openlabel-singlearm-prospective-multicenter-tandem-twostage-designed-phase-ii-study-to-evaluate-the-efficacy-of-fulvestrant-in-women-with-recurrentmetastatic-estrogen-receptorpositive-gynecological-malignancies-fuchsia-study(82bb6b14-67c9-43b4-a6dd-d8e53225ce35).html

Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy

Autori: Howell, Sacha J Howell, Anthony

Zdroj: Advances in Experimental Medicine and Biology ISBN: 9783031708749
Howell, S J & Howell, A 2025, Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy. in A Guide to Breast Cancer Research : From Cellular Heterogeneity and Molecular Mechanisms to Therapy. Advances in Experimental Medicine and Biology, vol. 1464, Springer Nature, pp. 449-474. https://doi.org/10.1007/978-3-031-70875-6_22

Predmety: Selective Estrogen Receptor Modulators, Antineoplastic Agents, Hormonal/therapeutic use, Antineoplastic Agents, Hormonal, Aromatase Inhibitors, Antineoplastic Agents, Breast Neoplasms, Breast Neoplasms/drug therapy, Estrogen Receptor Antagonists/therapeutic use, Receptors, Estrogen, Signal Transduction/drug effects, Selective Estrogen Receptor Modulators/therapeutic use, Receptors, Humans, Animals, Female, Estrogen/metabolism, Receptors, Estrogen/metabolism, Hormonal/therapeutic use, Molecular Targeted Therapy/methods, Aromatase Inhibitors/therapeutic use, Signal Transduction

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39821038
https://research.manchester.ac.uk/en/publications/79ac5dd8-2fdd-4734-bc60-6c0a12c34d02
https://doi.org/10.1007/978-3-031-70875-6_22

Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer

Autori: Klein, Evelyn Kiechle, Marion Josipovic, Adriana a ďalší

Zdroj: Breast Cancer Res Treat

Predmety: Adult, 0301 basic medicine, Receptor, ErbB-2, Research, Breast Neoplasms, Middle Aged, Breast cancer, Prognostic biomarker, Predictive biomarker, EndoPredict, Adjuvant chemotherapy, Risk stratification, Prognosis, Risk Assessment, Disease-Free Survival, ddc, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Receptors, Estrogen, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Female, Prospective Studies, Aged [MeSH], Receptor, ErbB-2/metabolism [MeSH], Neoplasm Recurrence, Local/pathology [MeSH], Neoplasm Staging [MeSH], Risk Assessment/methods [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Receptors, Progesterone/metabolism [MeSH], Humans [MeSH], Prospective Studies [MeSH], Treatment Outcome [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Biomarkers, Tumor/metabolism [MeSH], Disease-Free Survival [MeSH], Prognosis [MeSH], Neoplasm Recurrence, Local, Receptors, Progesterone, Aged, Neoplasm Staging

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38722442
https://repository.publisso.de/resource/frl:6521231
https://mediatum.ub.tum.de/1770720

Recreational physical activity and breast cancer risk by menopausal status and tumor hormone receptor status: results from the Nurses’ Health Studies

Autori: Renée T. Fortner Kristen D. Brantley Shelley S. Tworoger a ďalší

Zdroj: Breast Cancer Res Treat

Predmety: Adult, Epidemiology, Nurses, Breast Neoplasms, Middle Aged, Breast Neoplasms/etiology [MeSH], Female [MeSH], Postmenopause [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Premenopause [MeSH], Receptors, Progesterone/metabolism [MeSH], Humans [MeSH], Breast cancer, Middle Aged [MeSH], Risk Factors [MeSH], Breast Neoplasms/epidemiology [MeSH], Recreation [MeSH], Risk, Menopause [MeSH], Proportional Hazards Models [MeSH], Menopausal status, Physical activity, Hormone receptor status, Nurses/statistics, Exercise [MeSH], Postmenopause, 03 medical and health sciences, 0302 clinical medicine, Receptors, Estrogen, Premenopause, Risk Factors, Humans, Recreation, Female, Menopause, Receptors, Progesterone, Exercise, Proportional Hazards Models

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38592542
https://repository.publisso.de/resource/frl:6504517

Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer

Autori: Zimmer, Philipp Esser, Tobias Lueftner, Diana a ďalší

Zdroj: BMC Med
BMC Medicine, Vol 22, Iss 1, Pp 1-10 (2024)

Predmety: Quality of life, Survival, Breast Neoplasms, Körperliche Aktivität, Erschöpfung, Breast cancer, Germany, Brustkrebs, Humans, Female [MeSH], Aged [MeSH], Postmenopause [MeSH], Receptors, Estrogen/metabolism [MeSH], Humans [MeSH], Prospective Studies [MeSH], Progression-Free Survival [MeSH], Middle Aged [MeSH], Androstadienes/therapeutic use [MeSH], Fatigue [MeSH], Exercise/physiology [MeSH], Adverse events, Exercise, Breast Neoplasms [MeSH], Fatigue, Quality of Life [MeSH], Germany [MeSH], Physical activity, Research Article, Everolimus/therapeutic use [MeSH], Prospective Studies, Everolimus, Aged, Sport, Lebensqualität, Middle Aged, Progression-Free Survival, Letalität, Androstadienes, Postmenopause, Receptors, Estrogen, Quality of Life, Medicine, Female

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39379960
https://doaj.org/article/8b259c9cfcde41269ea27b87fe454bf7
https://repository.publisso.de/resource/frl:6499841

Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)

Autori: Guilherme Nader-Marta Christian Singer Dominik Hlauschek a ďalší

Zdroj: Breast Cancer Res
Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024)

Predmety: Endocrine therapy, Adult, Receptor, ErbB-2, Pyridines, Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Breast Neoplasms, Palbociclib, Middle Aged, Antibody–drug conjugates, Aged [MeSH], HER2-low, Receptor, ErbB-2/metabolism [MeSH], Breast cancer, Receptor, ErbB-2/genetics [MeSH], Neoplasm Staging [MeSH], Piperazines/therapeutic use [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Pyridines/therapeutic use [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Humans [MeSH], Breast Neoplasms/genetics [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Biomarkers, Tumor/metabolism [MeSH], Prognosis [MeSH], Prognosis, Piperazines, Receptors, Estrogen, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Female, RC254-282, Aged, Neoplasm Staging

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39375745
https://doaj.org/article/c4f4965043a847fba7a786c64cdbe554
https://repository.publisso.de/resource/frl:6500183

PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study

Autori: Ballé, Judith Katharina Vetter, Martina Kenea, Tariku Wakuma a ďalší

Zdroj: BMC Cancer
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)

Predmety: Adult, Rural Population, Survival, Receptor, ErbB-2, Breast Neoplasms, Ethiopia, Aged [MeSH], Intrinsic subtypes, Receptor, ErbB-2/metabolism [MeSH], Ethiopia/epidemiology [MeSH], Breast Neoplasms/therapy [MeSH], PAM50, Africa, Chemotherapy, Adjuvant/methods [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Receptors, Progesterone/metabolism [MeSH], Humans [MeSH], Prospective Studies [MeSH], Breast Neoplasms/genetics [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Breast Cancer, Rural Population [MeSH], Immunohistochemistry [MeSH], Biomarkers, Tumor/metabolism [MeSH], Research, Prognosis [MeSH], Gene Expression Profiling [MeSH], Biomarkers, Tumor, Humans, Prospective Studies, RC254-282, Aged, ddc:610, Gene Expression Profiling, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Prognosis, Immunohistochemistry, Receptors, Estrogen, Chemotherapy, Adjuvant, Female, Receptors, Progesterone

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39256703
https://doaj.org/article/d1d8fe71a42b4c2c90d5d660b7d42f77
https://repository.publisso.de/resource/frl:6490436

Associations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2− Tumors Treated with Adjuvant Hormonal Therapy: A Real‐World Study in Croatia

Autori: Dora Čerina Pavlinović Natalija Dedić Plavetić Ingrid Belac Lovasić a ďalší

Zdroj: Breast J
The Breast Journal, Vol 2024 (2024)

Predmety: Breast Neoplasms / drug therapy, Receptor, ErbB-2, receptor, receptors, Receptor, ErbB-2 / metabolism, chemotherapy, Class I Phosphatidylinositol 3-Kinases / genetics, ErbB-2, 0302 clinical medicine, breast neoplasms, estrogen, antineoplastic agents, RC254-282, Breast Neoplasms / mortality, breast tumor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Receptors, Estrogen / metabolism, Breast Neoplasms / therapy, Receptors, Progesterone / metabolism, Receptors, Estrogen, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal / therapeutic use, Breast Neoplasms / pathology, Female, PIK3CA mutations, Public aspects of medicine, RA1-1270, Receptors, Progesterone, Research Article, Adult, tumor, disease-free survival, Antineoplastic Agents, Hormonal, Class I Phosphatidylinositol 3-Kinases, Croatia, Neoplasm Recurrence, Local / genetics, Breast Neoplasms, progesterone, Disease-Free Survival, 03 medical and health sciences, adjuvant, local, Biomarkers, Tumor, Humans, Retrospective Studies, Aged, Receptor, ErbB-2 / genetics, biomarkers, neoplasm recurrence, hormonal, Biomarkers, Tumor / genetics, Breast Neoplasms / genetics, Mutation, mutation, Neoplasm Recurrence, Local

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39742376
https://doaj.org/article/58fd4feb40884d6bb8fd7ad6d6f40a50
https://onlinelibrary.wiley.com/doi/10.1155/2024/5648845
https://doi.org/10.1155/2024/5648845
https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.e12512
https://doi.org/10.1200/JCO.2024.42.16_suppl.e12512
https://urn.nsk.hr/urn:nbn:hr:105:788167
https://doi.org/10.1155/2024/5648845

On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer

Autori: Bruno Valentin Sinn Katharina Sychra Michael Untch a ďalší

Zdroj: Breast Cancer Res
Breast Cancer Research, Vol 26, Iss 1, Pp 1-11 (2024)

Predmety: Adult, Neoplasm, Residual, Receptor, ErbB-2, Biopsy, Breast Neoplasms, Disease-Free Survival, Breast cancer, Lymphocytes, Tumor-Infiltrating, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, TILs, RC254-282, Aged, Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Serial biopsies, Middle Aged, Prognosis, Neoadjuvant Therapy, Ki-67 Antigen, Treatment Outcome, Receptors, Estrogen, Chemotherapy, Adjuvant, Neoadjuvant therapy, Aged [MeSH], Receptor, ErbB-2/metabolism [MeSH], Neoadjuvant Therapy/methods [MeSH], Ki-67 Antigen/metabolism [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Biopsy [MeSH], Receptors, Progesterone/metabolism [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Lymphocytes, Tumor-Infiltrating/metabolism [MeSH], Neoplasm, Residual/pathology [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Lymphocytes, Tumor-Infiltrating/immunology [MeSH], Biomarkers, Tumor/metabolism [MeSH], Disease-Free Survival [MeSH], Prognosis [MeSH], Ki-67, Female, Receptors, Progesterone

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39317942
https://doaj.org/article/7254adee1eef456f91cca8c6f84490e2
https://repository.publisso.de/resource/frl:6503837

EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis

Autori: Glotzbach, Annika Rohlf, Katharina Gonscharow, Anastasia a ďalší

Zdroj: Breast Cancer Res
Breast Cancer Research, Vol 26, Iss 1, Pp 1-20 (2024)

Predmety: Glycerophospholipid metabolism, 0301 basic medicine, Lung Neoplasms, Receptor, ErbB-2, Cell Line, Tumor [MeSH], Receptor, ErbB-2/metabolism [MeSH], Lung Neoplasms/genetics [MeSH], Metastasis, Breast cancer, Cell Movement [MeSH], Receptor, ErbB-2/genetics [MeSH], Tumor Burden [MeSH], Disease Models, Animal [MeSH], HER2 positive breast cancer, Breast Neoplasms/pathology [MeSH], Anoikis, Female [MeSH], Cell Proliferation [MeSH], Phospholipases/genetics [MeSH], Receptors, Estrogen/metabolism [MeSH], Humans [MeSH], Neoplasm Metastasis [MeSH], Breast Neoplasms/genetics [MeSH], Gene Knockdown Techniques [MeSH], Breast Neoplasms/metabolism [MeSH], Animals [MeSH], GPCPD1, Mice [MeSH], Phospholipases/metabolism [MeSH], Research, Lung Neoplasms/pathology [MeSH], Lung Neoplasms/metabolism [MeSH], Choline metabolism, Lung Neoplasms/secondary [MeSH], Breast Neoplasms, Mice, 03 medical and health sciences, Cell Movement, Cell Line, Tumor, Animals, Humans, Neoplasm Metastasis, RC254-282, Cell Proliferation, 0303 health sciences, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Tumor Burden, 3. Good health, Disease Models, Animal, Receptors, Estrogen, Phospholipases, Gene Knockdown Techniques, Female

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38816770
https://doaj.org/article/f5f898d38fee442c8efa7d5ee8240227
https://repository.publisso.de/resource/frl:6524446

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

Autori: Kuemmel S. Harper-Wynne C. Park Y. H. a ďalší

Zdroj: BMC Cancer
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)

Predmety: Breast cancer, Estrogen receptor-positive, Giredestrant, HER2-positive, Pertuzumab, Trastuzumab, Adult, 0301 basic medicine, Receptor, ErbB-2, Injections, Subcutaneous, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Study Protocol, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasm Metastasis, RC254-282, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, 3. Good health, Receptors, Estrogen, Receptor, ErbB-2/metabolism [MeSH], Trastuzumab/administration, Antibodies, Monoclonal, Humanized/administration, Trastuzumab/therapeutic use [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Humans [MeSH], Neoplasm Metastasis [MeSH], Breast Neoplasms/genetics [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH], Injections, Subcutaneous [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Antibodies, Monoclonal, Humanized/adverse effects [MeSH], Female

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38789924
https://doaj.org/article/e5f45a7c5b7e4bb7bb99b0bb30af3b2c
https://hdl.handle.net/11588/963524
https://repository.publisso.de/resource/frl:6504043

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial: overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Autori: Howell, Sacha J Casbard, Angela Carucci, Margherita a ďalší

Zdroj: Lancet Oncol
Howell, S J, Casbard, A, Carucci, M, Ingarfield, K, Butler, R, Morgan, S, Meissner, M, Bale, C, Bezecny, P, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, de Bruin, E C, Schiavon, G, Foxley, A & Jones, R H 2022, 'Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION) : overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial', The Lancet. Oncology, vol. 23, no. 7, pp. 851-864. https://doi.org/10.1016/S1470-2045(22)00284-4

Predmety: Adult, Phosphatidylinositol 3-Kinases/genetics, Adolescent, Receptor, ErbB-2, Receptor, ErbB-2/metabolism, Breast Neoplasms, Phosphatidylinositol 3-Kinases, Breast Neoplasms/drug therapy, Double-Blind Method, Receptors, Antineoplastic Combined Chemotherapy Protocols, Humans, Pyrroles, Neoplasm Recurrence, Local/pathology, Fulvestrant, Manchester Cancer Research Centre, Aromatase Inhibitors, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Articles, 16. Peace & justice, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre, Progression-Free Survival, 3. Good health, Neoplasm Recurrence, Pyrimidines, Receptors, Estrogen, ErbB-2/metabolism, Female, Estrogen/metabolism, Receptors, Estrogen/metabolism, Neoplasm Recurrence, Local, Proto-Oncogene Proteins c-akt, Local/pathology, Aromatase Inhibitors/therapeutic use, Receptor

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/35671774
https://orca.cardiff.ac.uk/id/eprint/150340/1/1-s2.0-S1470204522002844-main.pdf
https://research.manchester.ac.uk/en/publications/9709b095-c00d-4f89-a76b-ad6abaabc582
https://doi.org/10.1016/S1470-2045(22)00284-4

Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903): The PARAGON trial (ANZGOG 0903)

Autori: Edmondson, R J O'Connell, R L Banerjee, S a ďalší

Prispievatelia: Edmondson, R J O'Connell, R L Banerjee, S a ďalší

Zdroj: PARAGON investigators 2021, 'Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus : The PARAGON trial (ANZGOG 0903)', Gynecologic Oncology, vol. 163, no. 3, pp. 524-530. https://doi.org/10.1016/j.ygyno.2021.09.010

Predmety: Adult, Leiomyosarcoma, 0301 basic medicine, Carcinosarcoma/drug therapy, Receptors, Progesterone/metabolism, Sustainable Development Goals, Anastrozole, uterine carcinosarcoma, uterine leiomyosarcoma, 03 medical and health sciences, 0302 clinical medicine, Carcinosarcoma, Uterine Neoplasms/drug therapy, Uterine leiomyosarcoma, Receptors, 80 and over, Humans, Prospective Studies, Neoplasm Metastasis, SDG 3, Aged, Aged, 80 and over, Manchester Cancer Research Centre, Uterine carcinosarcoma, Aromatase Inhibitors, Leiomyosarcoma/drug therapy, Anastrozole/adverse effects, Aromatase inhibitor, Middle Aged, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre, 3. Good health, Receptors, Estrogen, aromatase inhibitor, Uterine Neoplasms, Quality of Life, Progesterone/metabolism, Female, Aromatase Inhibitors/adverse effects, Estrogen/metabolism, Receptors, Estrogen/metabolism, Receptors, Progesterone

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/34625284
https://research.manchester.ac.uk/en/publications/a4447fca-4b40-4043-bd44-5f411c01edde
https://doi.org/10.1016/j.ygyno.2021.09.010
https://chesterrep.openrepository.com/handle/10034/626171
https://www.sciencedirect.com/science/article/pii/S0090825821013792
https://pubmed.ncbi.nlm.nih.gov/34625284/
https://www.gynecologiconcology-online.net/article/S0090-8258(21)01379-2/fulltext

Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer: a prospective cohort study

Autori: Somayeh Khazaei Ana Bosch Karin Jirström a ďalší

Zdroj: Carcinogenesis
Godina, C, Khazaei, S, Tryggvadottir, H, Visse, E, Nodin, B, Jirström, K, Borgquist, S, Bosch, A, Isaksson, K & Jernström, H 2021, 'Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer : A prospective cohort study', Carcinogenesis, vol. 42, no. 11, pp. 1314-1325. https://doi.org/10.1093/carcin/bgab090

Predmety: RNA, Messenger/genetics, DOWN-REGULATION, Receptors, Progesterone/metabolism, Datasets as Topic, ALCOHOL, Breast Neoplasms, THERAPY, 03 medical and health sciences, 0302 clinical medicine, FACTOR-I RECEPTOR, Humans, Prospective Studies, RNA, Messenger, Cancer Biomarkers and Molecular Epidemiology, GENE-EXPRESSION, Insulin-Like Growth Factor Binding Proteins/genetics, Aged, Middle Aged, Prognosis, 3. Good health, Insulin-Like Growth Factor Binding Proteins, ESTROGEN-RECEPTOR, Receptors, Estrogen, Breast Neoplasms/metabolism, ENDOCRINE TREATMENT, Female, Receptors, Estrogen/metabolism, Receptors, Progesterone, RESISTANCE

Popis súboru: application/pdf

Prístupová URL adresa: https://academic.oup.com/carcin/article-pdf/42/11/1314/41138082/bgab090.pdf
https://pubmed.ncbi.nlm.nih.gov/34606580
https://academic.oup.com/carcin/article/42/11/1314/6380882
https://pure.au.dk/ws/files/274258204/bgab090.pdf
https://pure.au.dk/ws/files/274258204/bgab090.pdf
https://pure.au.dk/portal/en/publications/0d285037-b48c-42f4-a54c-53bf2bc87cb6
https://doi.org/10.1093/carcin/bgab090
http://www.scopus.com/inward/record.url?scp=85121109873&partnerID=8YFLogxK

Expression of estrogen-related receptors in ovarian cancer and impact on survival

Autori: Schüler-Toprak, Susanne Weber, Florian Skrzypczak, Maciej a ďalší

Zdroj: J Cancer Res Clin Oncol

Predmety: Ovarian Neoplasms, ERRalpha Estrogen-Related Receptor, ddc:610, 610 Medizin, Prognosis, Adenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Endometrial Neoplasms, 3. Good health, Survival Rate, 03 medical and health sciences, 0302 clinical medicine, Receptors, Estrogen, Cystadenocarcinoma, Serous/pathology [MeSH], Ovarian Neoplasms/mortality [MeSH], Cystadenocarcinoma, Serous/metabolism [MeSH], Adenocarcinoma, Mucinous/mortality [MeSH], Endometrial Neoplasms/mortality [MeSH], Tissue microarray, Ovarian Neoplasms/metabolism [MeSH], Estrogen-related receptors, Adenocarcinoma, Clear Cell/metabolism [MeSH], Ovarian Neoplasms/pathology [MeSH], Adenocarcinoma, Mucinous/metabolism [MeSH], Female [MeSH], Endometrial Neoplasms/metabolism [MeSH], Follow-Up Studies [MeSH], Original Article – Cancer Research, Receptors, Estrogen/metabolism [MeSH], Ovarian cancer, Humans [MeSH], Overall survival, Retrospective Studies [MeSH], Cystadenocarcinoma, Serous/mortality [MeSH], Adenocarcinoma, Clear Cell/mortality [MeSH], Survival Rate [MeSH], Endometrial Neoplasms/pathology [MeSH], Adenocarcinoma, Clear Cell/pathology [MeSH], Biomarkers, Tumor/metabolism [MeSH], Adenocarcinoma, Mucinous/pathology [MeSH], Prognosis [MeSH], Progression-free survival, Estrogen-related receptors, Ovarian cancer, Overall survival, Progression-free survival, Tissue microarray, Biomarkers, Tumor, Humans, Female, Adenocarcinoma, Clear Cell, Follow-Up Studies, Retrospective Studies

Popis súboru: application/pdf

Prístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s00432-021-03673-9.pdf
https://pubmed.ncbi.nlm.nih.gov/34089362
https://link.springer.com/content/pdf/10.1007/s00432-021-03673-9.pdf
https://www.ncbi.nlm.nih.gov/pubmed/34089362
https://epub.uni-regensburg.de/45989/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310835
https://link.springer.com/article/10.1007/s00432-021-03673-9
https://pubmed.ncbi.nlm.nih.gov/34089362/
https://link.springer.com/article/10.1007/s00432-021-03673-9
https://doi.org/10.1007/s00432-021-03673-9
https://repository.publisso.de/resource/frl:6449854
https://epub.uni-regensburg.de/45989/

Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma

Autori: Anne Tardivon Anne Vincent-Salomon Caroline Saint-Martin a ďalší

Prispievatelia: Anne Tardivon Anne Vincent-Salomon Caroline Saint-Martin a ďalší

Zdroj: Modern pathology, Vol. 33, No 11 (2020) pp. 2198-2207

Predmety: Receptor, ErbB-2, [SDV]Life Sciences [q-bio], Carcinoma, Lobular / immunology, Breast Neoplasms, ddc:616.07, 616.07, Receptor, ErbB-2 / metabolism, Breast Neoplasms / metabolism, Breast Neoplasms / immunology, Carcinoma, Lobular / mortality, 03 medical and health sciences, Lymphocytes, Tumor-Infiltrating, 0302 clinical medicine, Lymphocytes, Tumor-Infiltrating / immunology, Humans, Carcinoma, Lobular / metabolism, Retrospective Studies, Breast Neoplasms / mortality, Carcinoma, Lobular / pathology, Age Factors, Middle Aged, Prognosis, Receptors, Estrogen / metabolism, 3. Good health, [SDV] Life Sciences [q-bio], Survival Rate, Carcinoma, Lobular, Receptors, Progesterone / metabolism, Receptors, Estrogen, Breast Neoplasms / pathology, Female, Receptors, Progesterone, Lymphocytes, Tumor-Infiltrating / pathology

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/32404955
https://hal.archives-ouvertes.fr/hal-03032297
https://www.nature.com/articles/s41379-020-0561-9.pdf
https://www.ncbi.nlm.nih.gov/pubmed/32404955
https://archive-ouverte.unige.ch/unige:155787
https://www.nature.com/articles/s41379-020-0561-9
https://pubmed.ncbi.nlm.nih.gov/32404955/
https://archive-ouverte.unige.ch/unige:155787

Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status

Autori: Elinborg J. Olafsdottir Ake Borg Maj-Britt Jensen a ďalší

Zdroj: Br J Cancer
Olafsdottir, E J, Borg, A, Jensen, M-B, Gerdes, A-M, Johansson, A L V, Barkardottir, R B, Johannsson, O T, Ejlertsen, B, Sønderstrup, I M H, Hovig, E, Lænkholm, A-V, Hansen, T V O, Olafsdottir, G H, Rossing, M, Jonasson, J G, Sigurdsson, S, Loman, N, Nilsson, M P, Narod, S A & Tryggvadottir, L 2020, ' Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status ', British Journal of Cancer, vol. 123, no. 11, pp. 1608-1615 . https://doi.org/10.1038/s41416-020-01056-4

Predmety: Adult, Aged, 80 and over, BRCA2 Protein, Heterozygote, Breast Neoplasms, Breast Neoplasms/genetics, Middle Aged, Scandinavian and Nordic Countries, BRCA2 Protein/genetics, Article, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Receptors, Estrogen, Receptors, Mutation, 80 and over, Humans, Female, Genetic Predisposition to Disease, Estrogen/metabolism, Receptors, Estrogen/metabolism, Aged

Popis súboru: application/pdf

Prístupová URL adresa: https://www.nature.com/articles/s41416-020-01056-4.pdf
https://pubmed.ncbi.nlm.nih.gov/32939053
https://www.ncbi.nlm.nih.gov/pubmed/32939053
https://portal.research.lu.se/en/publications/breast-cancer-survival-in-nordic-brca2-mutation-carriersunconvent
https://www.nature.com/articles/s41416-020-01056-4
https://europepmc.org/article/PMC/PMC7686356
https://pubmed.ncbi.nlm.nih.gov/32939053/
https://lup.lub.lu.se/search/publication/0b4cc50f-f6df-4cff-a226-c48768744d93
https://curis.ku.dk/ws/files/288874261/Breast_cancer_survival_in_Nordic_BRCA2_mutation_carriers_unconventional_association_with_oestrogen_receptor_status_publisher_version_ccby_.pdf

Zinc distribution within breast cancer tissue of different intrinsic subtypes

Autori: Peter Rusch Alfred V. Hirner Oliver Schmitz a ďalší

Zdroj: Arch Gynecol Obstet

Predmety: Adult, 2. Zero hunger, 0301 basic medicine, 0303 health sciences, Receptor, ErbB-2, Chemie, Medizin, Breast Neoplasms, Pilot Projects, Gynecologic Oncology, Middle Aged, Aged [MeSH], Receptor, ErbB-2/metabolism [MeSH], Breast cancer, Receptors, Progesterone/analysis [MeSH], Germany/epidemiology [MeSH], Feasibility Studies [MeSH], Receptor, ErbB-2/analysis [MeSH], Biomarker, Zinc, Zinc/metabolism [MeSH], Zinc/analysis [MeSH], Biomarkers, Tumor/analysis [MeSH], Steroid receptor, Breast Neoplasms/pathology [MeSH], Laser Therapy [MeSH], Female [MeSH], Human epidermal growth factor receptor 2, Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Receptors, Progesterone/metabolism [MeSH], Humans [MeSH], Breast Neoplasms/chemistry [MeSH], Middle Aged [MeSH], Zinc/chemistry [MeSH], Laser ablation inductively coupled mass spectrometry (LA-ICPMS), Biomarkers, Tumor/metabolism [MeSH], Pilot Projects [MeSH], Mass Spectrometry/methods [MeSH], Receptors, Estrogen/analysis [MeSH], Mass Spectrometry, 3. Good health, 03 medical and health sciences, Receptors, Estrogen, Germany, Biomarkers, Tumor, Feasibility Studies, Humans, Female, Laser Therapy, Receptors, Progesterone, Aged

Prístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s00404-020-05789-8.pdf
https://pubmed.ncbi.nlm.nih.gov/32930875
https://pubmed.ncbi.nlm.nih.gov/32930875/
https://europepmc.org/article/MED/32930875
https://link.springer.com/content/pdf/10.1007/s00404-020-05789-8.pdf
https://link.springer.com/article/10.1007/s00404-020-05789-8
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854450
https://www.ncbi.nlm.nih.gov/pubmed/32930875
https://repository.publisso.de/resource/frl:6466708
https://www.ncbi.nlm.nih.gov/pubmed/32930875
https://doi.org/10.1007/s00404-020-05789-8
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85090995657